Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined forces with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s patented DehydraTECHÔ technology to potentially commercialize a form of oral nicotine delivery. An article discussing the company reads, “Lexaria’s goal is to create an oral product that eliminates the need for inhalation and helps curb the smoking habits of consumers. Over 6 million deaths a year worldwide are attributed to nicotine delivery through smoking. The company believes that its DehydraTECH technology may help the 69 percent of U.S. adult smokers who want to quit move from cigarettes to a safer, more effective delivery of nicotine (http://ibn.fm/Aps9F). This new partnership allows for further research and development into oral, reduced-risk nicotine consumer products.”
To view the full article, visit http://ibn.fm/ndG0V
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10 patents granted in the United States and Australia, and has filed over 50 patent applications worldwide across 10 patent families. Lexaria’s technology provides more rapid delivery to the bloodstream, as well as important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
